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Abstract 
We have recently demonstrated that Aurora-A kinase is a potential oncogene to develop 
mammary gland tumors in mice, when expressed under MMTV promoter. These tumors 
contain phosphorylated forms of Akt and mTOR, suggesting that Akt-mTOR pathway is 
involved in transformed phenotype induced by Aurora-A. In the present studies, we dis-
covered that stable cell lines expressing Aurora-A contain phosphorylation of Akt Ser473 
after prolonged passages of cell culture, not in cells of the early period of cell culture. Levels 
of PTEN tumor suppressor are significantly reduced in these late passage cells at least in part 
due to increased poly ubiquitination of the protein. Akt-activated Aurora-A cells formed 
larger colonies in soft agar and are resistant to UV-induced apoptosis. Aurora-A inhibitor, 
VX-680, can cause cell death of Aurora-A cells in which Akt is not activated. 
siRNA-mediated depletion of mTOR in those cells resulted in decreased phosphorylation of 
Akt Ser473, suggesting that TORC2 complex phosphorylates Akt in Aurora-A cells. Treat-
ment of late-passage Aurora-A cells with mTOR inhibitor reduced colony formation in soft 
agar. These results strongly suggest that commitment of cell transformation by Aurora-A is 
determined by at least co-activation of Akt/mTOR pathway. 
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INTRODUCTION 
The Aurora family of kinase consists of three re-
lated proteins (Aurora-A, B and C) that share the high 
sequence homology in their catalytic domains (1,2). 
Among them is Aurora-A that regulates mitotic pro-
gression in various organisms (1). It has been well 
documented that activation of Aurora-A is required 
for mitotic entry, centrosome maturation and separa-
tion, and G2 to M transition (1,3). Overexpression of 
Aurora-A is frequently observed in varieties of hu-
man cancer, including breast, colorectal, bladder, 
pancreatic, gastric, ovarian and esophageal cancer 
(4-9). Significantly, overexpression of Aurora-A in 
fibroblasts resulted in cell transformation, supporting 
a notion that high levels of this protein are correlated 
to cell malignancy. 
Potential roles of Aurora-A in cell transforma-
tion were also demonstrated from recent studies that 
this kinase phosphorylates a breast cancer tumor 
suppressor BRCA1 at Ser308 (10). This phosphoryla-
tion occurs at G2 to M transition and is necessary for 
the entry into mitosis. Interestingly, BRCA1-negative 
fibroblasts re-expressing phospho-deficient BRCA1 
are arrested in G2 phase without DNA damage. In 
studies using mice, we demonstrated that, when 
Aurora-A is expressed under control of MMTV pro-
moter, mammary tumors are developed, providing Int. J. Biol. Sci. 2009, 5 
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direct evidence that this kinase can function as an 
oncogene in vivo, although latency is quite long (1,5 to 
2 years) (11). Immunohistochemical analysis showed 
that mTOR and Akt are highly phosphorylated in 
these tumors (11). These results strongly suggest that 
Aurora-A activates mTOR/Akt pathway in the proc-
ess of cell transformation. 
Many small chemical compounds of Aurora 
kinase inhibitors are currently undergoing preclinical 
and clinical assessment. VX-680 is one of the pio-
neering chemicals in these trials (12). It is a pyrimidine 
derivative with high affinity for Aurora-A, B and C at 
nanomolar concentrations. VX-680 prevents cytoki-
nesis but allows cells to progress through the other 
stages of mitosis, which leads to polyploidy and, in 
some cancer cell lines, massive cell death. In preclini-
cal models, VX-680 blocked tumor xenograft growth 
and induced regression of the tumors (12). 
In this study, we investigated the biological and 
biochemical phenotype of cells overexpressing 
Aurora-A using established cell lines of different 
passage numbers. We discovered that more malignant 
phenotype is observed in Aurora-A cells containing 
activated mTOR/Akt pathway, which occurred only 
when Aurora-A cells are maintained for longer pas-
sage. These results suggest that overexpression of 
Aurora-A does not induce malignant phenotypes 
immediately, and that it cooperates with other onco-
genic pathway for the full transformation. 
 
 
EXPERIMENTAL PROCEDURES 
Cell culture and western blotting.  
U2OS human osteosarcoma cell line was grown 
in DMEM containing 10% fetal bovine serum and 
100U of penicillin-streptomycin/ml. Cells were 
transfected with FLAG-Aurora-A/pcDNA3 and 
maintained in the presence of G418 (700μg/ml) for 7 
days. Three independent clones (clone 1, 2 and 3) 
were isolated. For Western blot analysis, cells were 
lysed in EBC buffer (50 mM Tris-HCl, pH 8.0, 120 nM 
NaCl, 0.5% Nonidet P-40, 100 mM NaF, 200 μM so-
dium orthovanadate, 100 μg/ml phenylmethylsul-
fonyl fluoride, 2 μg/ml leupeptin, 2 μg/ml aprotinin). 
Protein concentration in cell lysates were determined 
using the Bio-Rad protein assay kit. Sixty micrograms 
of whole cell extract were loaded per lane and sepa-
rated by 6, 7.5% or 12% SDS-PAGE. Transfer to Im-
mobilon-P membrane (Milipore, Billercia, MA) was 
performed using a semidry transfer method 
(Trans-Blot; Bio-Rad, Hercules, CA) in 25 mM Tris 
base, 192 mM glycine and 10% methanol for 1.5 h at 
15V. Membranes were blocked in 1% nonfat dried 
milk in phosphate-buffered saline/0.05% Tween and 
incubated with primary antibodies and horseradish 
peroxidase-conjugated secondary antibodies (Jackson 
Laboratories, Westgrove, PA) followed by ECL detec-
tion. For immunoprecipitation, 1 mg of total cell lysate 
was incubated with the specific antibody over night at 
4°C followed by either protein A- or protein-G 
Sepharose beads (Sigma, St. Louis, MO). The samples 
were washed with NET-N buffer and subjected to 
SDS-PAGE. 
siRNA Assay 
Synthesized siRNA (#6381 and #6556) were 
purchased from Cell Signaling and tested for sup-
pression. Briefly, U2OS cells were seeded at 30% con-
fluence the day prior to transfection and cells were 
transfected with FuGENE (Roche Applied Science, 
Indianapolis, IN). Twenty-four hours later, transfec-
tions were repeated as before. Lysates were collected 
after a further 48hr and subjected to SDS-PAGE. 
#6381 were used for the experiments since it showed 
better suppression. 
Plasmids and antibodies.  
Expression vectors for HA-ubiquitin and PTEN 
in pcDNA3 were from Dr. A. Chan at the Mt. Sinai 
School of Medicine. FLAG-tagged Aurora-A cDNA 
was expressed with pcDNA3. The antibodies for HA 
tag, PTEN (A2B1), p53 (DO-1), PI3K (D-4) and Akt 
(B-1) were purchased from Santa Cruz. The antibodies 
for Akt phospho-Ser473, p53 phospho-Ser15, and 
ATR, DNA-PK were purchased from Cell Signaling. 
The antibody for ATM was purchased from Rockland.  
Annexin V/PI staining.  
Cells were washed with PBS and harvested by 
trypsinization and the concentration adjusted to 1x106 
cells/ml. Annexin V was detected using an Annexin 
V-FITC Apoptosis Detection Kit (Oncogene Research) 
as recommended by the manufacturer. VX-680 was 
provided by Vertex/Merck. 
 
Assays for colony formation in soft agar and cell 
growth 
Six well plates were filled with 2 ml of 0.6% no-
ble agar (Invitrogen) in DMEM supplemented with 
10% calf serum as a bottom layer and allowed to so-
lidify at 4oC overnight. 104 cells were suspended in 1 
ml of 0.4% agarose. Cell culture plates were main-
tained for 2 weeks in a CO2 incubator. For cell growth, 
106 cells were seeded on the plates and cell numbers 
were counted every day in duplicate. 
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RESULTS 
Elevated Phosphorylation of Akt Ser473 in 
Aurora-A expressing cell culture. 
We have previously shown that 
MMTV-Aurora-A transgene developed mammary 
gland tumors that expressed phosphorylated mTOR 
and Akt (11). To study the mechanism of how Akt 
pathway is activated by Aurora-A, we established 
stable cell lines overexpressing Aurora-A. U2OS cells 
were chosen because p53 is wild type and highly 
transfectable. Cells were transfected with a plasmid 
encoding FLAG-tagged Aurora-A cDNA regulated by 
CMV promoter. After maintained in the presence of 
G418 for seven days (passage-number = 0), we started 
to count the passage numbers every time we seeded 
cell culture. Aurora-A cells at passage number 10, 20 
and 40 (termed A-10, A-20 and A-40 cells, respec-
tively) were studied as below. Levels of 
Flag-Aurora-A, phosphorylation of Akt at Ser473, 
PTEN and p53 were immunoblotted using lysates of 
A-10, A-20 and A-40 cells.  
Three independent clones were isolated and 
immunoblotted with the indicated antibodies (Fig.1). 
Levels of Flag-Aurora-A were slightly decreased in 
A-40 cells, compared to those in A-10 and A-20 cells. 
Constitutive phosphorylation of Akt at Ser473 was 
similar in both control cells and A-10 cells, however, it 
increased significantly in A-20 and A-40 cells. It has 
been well documented that PTEN functions upstream 
of Akt, and negatively regulates Akt activity (13,14). 
Levels of PTEN increased in A-10 cells, but became 
lower in A-40 cells than those of control cells. Levels 
of both p53 and phosphorylation of p53 Ser15 were 
also increased in A-10 cells, and decreased in A-20 
and A-40 cells. These results suggest that 
p53-mediated checkpoint is transiently activated in 
Aurora-A cells of early passage number. Since it has 
been shown that p53 directly regulates the genomic 
promoter of PTEN (15), it is suggested that activated 
p53 increased levels of PTEN in A-10 cells. 
To further explore the mechanism of lowered 
levels of PTEN in Aurora-A cells, poly-ubiquitination 
of PTEN was studied in both vector cells of pas-
sage-number of 40 and A-40 cells. Cells were trans-
fected with PTEN and HA-ubiquititn under treatment 
with MG132, a proteasome inhibitor. As demon-
strated in Fig. 2, poly-ubiquitination of PTEN was 
much increased in A-40 cells compared to those in 
vector control cells. These results indicate that levels 
of PTEN are down-regulated in ubiquitin-dependent 
manner in A-40 cells. 
 
FIG. 1. Increased phosphorylation of Akt Ser473 in 
Aurora-A overexpressing cells. U2OS cells were trans-
fected with FLAG-Aurora-A and maintained with G418 
(700μg/ml) for 7 days. Isolated clones (clone 1, 2 and 3) 
were expanded and immunoblotted with the indicated 
antibodies.  
 
FIG. 2. Increased poly-ubiquitination of PTEN in A-40 cells. 
A-40 cells and control cells transfected with a vector 
(passage number 40) were transfected with PTEN and 
HA-ubiquitin for 2 days. Cells were treated with MG-132 
(SIGMA, 5 μM, 12 hr) PTEN was immunoprecipitated and 
samples were immunoblotted with anti HA antibody.  
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Colony Formation Ability of Aurora-A Cells is 
Enhanced After Increased Passage 
Next, we characterized colony formation and cell 
growth of Aurora-A expressing cells. We used vec-
tor-transfected cells of passage-number of 40, A-10 
and A-40 cells. Same numbers of these cells (1 x 104 
cells) were plated in soft agar, and colony forming 
ability was determined after 14 days. Although U2OS 
cells are originally human cancer cells, the size of the 
colonies in soft agar was small. However interest-
ingly, A-10 cells could form slightly larger colonies 
than control cells, and A-40 cells formed much larger 
colonies (Fig. 3A).  
Cell growth was determined for 7 days using the 
same set of cells that were used in colony formation 
assay. Compared to the control cells, cell proliferation 
of both A-10 and A-40 cells were faster, however no 
significant differences in A-10 and A-40 cells were 
found (Fig. 3B). These results suggest that cells ex-
pressing high levels of Aurora-A immediately pro-
mote enhanced advantage of cell growth, but malig-
nant phenotype of anchorage-independency is ac-
quired later, resulting from after increased cell divi-
sion. Colony formation assay and cell growth assay 
were examined using other Aurora-A clones de-
scribed in Fig.1, and all clones showed the similar 
phenotypes (data not shown).  
 
 
FIG. 3. Colony formation and cell growth assay. (A) Control cells, A-10 cells and A-40 cells were seeded in agar plate and 
colony formation was studied after 14 days. A scale bar is shown. (B) Cells were seeded in cell culture plates in duplicate and 
numbers were counted every day for 7 day. 
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Suppression of Cell Death of Aurora-A Cells 
We examined expression of Aurora-A affects 
induction of cell death under conditions of apoptotic 
stimuli. Vector control U2OS cells of passage-number 
of 40, A-10 and A-40 cells were treated with UV 
damage (100mJ/cm2), and cell death was measured 
with Annexin V staining after 12 hr (Fig. 4A). Al-
though UV treatment induced significant cell death of 
control cells (35.2%), A-10 and A-40 cells showed re-
sistance to cell death under the same conditions, al-
though A-10 cells showed slightly more resistance 
(6.46% and 15.37%, respectively). Basal levels of 
apoptosis of both A-10 and A-40 cells without UV 
stimulation were similar to those of control cells 
(0.49%, and data not shown). 
Next, sensitivity of Aurora-A cells to VX-680, an 
Aurora-A kinase inhibitor (12), was studied. Vector 
control cells, A-10 and A-40 were treated with differ-
ent concentration of VX-680 for 12 hr, and cell death 
was measured by Annexin V staining (Fig. 4B). Al-
though control cells did not show significant cell 
death in these conditions, higher levels of cell death of 
A-10 cells were observed in dose dependent manner. 
Interestingly, A-40 cells were resistant to 
VX-680-induced cell death in these experiments. We 
examined different clones of Aurora-A cells (see 
Fig.1), but all of long-passaged cells showed similar 
resistance to VX-680. 
 
FIG. 4. A-40 cells are resistant to both UV and VX-680. (A) Control, A-10 and A-40 cells were treated with UV 
(100mJ/cm
2) and apoptosis was studied with Annexin V stain. (B) Indicated cells were treated with VX-680 for 12 hr and 
apoptosis was determined by Annexin V stain. 
 
mTOR is Responsible for Phosphorylation of Akt 
Ser473 in Aurora-A Cells 
Roles of Akt in cell transformation have been 
well illustrated. Recent studies have demonstrated 
that TORC2 complex that contains mTOR, mLST8, 
Rictor, mSin1 and Protor phosphorylates Akt at 
Ser473 (16-18). To understand the mechanism of 
Aurora-A’s cell transformation, we studied how Akt 
phosphorylation is regulated in these cells. First, vec-
tor control cells of passage-number of 40 and three 
independent clones (clone 1, 2 and 3, see Fig.1) of A-40 
cells were treated with wortmannin, a general PI3K 
(phosphoinositide 3 kinase) inhibitor (Fig. 5A). 
Phosphorylation of Akt Ser473 was significantly in-
hibited with this treatment in all of three clones, sug-
gesting that PI3K members of proteins are involved in 
this phosphorylation of Akt in Aurora-A cells. 
There are several protein kinases that belong to 
PI3K family. These include, ATM (ataxia telangiecta-
sia mutated), ATR (ATM-related), DNA-PK, PI3K and 
mTOR. Among the kinases tested, depletion of mTOR 
but not other kinases resulted in inhibition of phos-
phorylation of Akt at Ser473 (Fig.5B and data not 
shown). Cells transfected with scrambled siRNA did 
not show the decreased phosphorylation of Akt 
Ser473. When A-40 cells were treated with rapamycin 
for 12 hr, increased cell death was observed (Fig.5C). 
These results strongly suggest that Akt Ser473 in 
Aurora-A cells is phosphorylated by mTOR, and that 
mTOR-Akt pathway activated in Aurora-A cells is 
essential for cell transformation induced by Aurora-A. Int. J. Biol. Sci. 2009, 5 
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FIG. 5. Akt Ser473 is phosphorylated by mTOR in Aurora-A cells. (A) Control and Aurora-A cells of passage number of 40 
(clone 1, 2 and 3, see Fig.1) were treated with wortmannin (4 μM, 2 hr), and immunoblotted with the indicated antibodies. 
(B) A-40 cells were transfected with siRNA for mTOR for 48 hr. Cell lysates were immunoblotted with the indicated 
antibodies. (C) A-40 cells were treated with rapamycin (1 μM, 12 hr) and apoptosis was determined by Annexiv V stain. 
 
DISCUSSION 
Our previous studies have illustrated that tissue 
specific expression of Aurora-A kinase in mammary 
gland can develop mammary tumors in mice, pro-
viding direct evidence that this kinase is oncogenic in 
animal model (11). Tumor incidence in these mice are 
however low (30 to 40%) and their latency is signifi-
cantly long (more than 1 year), suggesting that onco-
genic potential of Aurora-A is not as high as other 
oncogenes, such as MMTV-neu mice (19). In our im-
munohistochemical studies, we discovered that 
mTOR/Akt pathway was activated in tumors devel-
oped in these mice, although the role and mechanisms 
of this activation were not clear.  
In the present studies, we explored how 
Aurora-A and mTOR/Akt pathway collaborate for 
cell transformation. We discovered that activation of 
mTOR/Akt does not occur immediately after over-
expression of Aurora-A in U2OS cells. Consistent with 
these results, we found that transient expression of 
Aurora-A in human embryonic kidney cell line, 293 
cells, does not cause phosphorylation of Akt and 
mTOR (data not shown). We are in the midst of in-
vestigating how Aurora-A activates mTOR/Akt 
pathway by transiently or stably expressing Aurora-A 
in other cell lines. 
It was found that levels of p53 is induced in cells 
of early passage numbers p53, which returned to the 
control levels after prolonged cell culture. Mammary 
tumor development induced by MMTV-Aurora-A 
was accelerated on p53(+/-) background (11). These 
results support the notion that p53 plays a role of a 
gate-keeper in Aurora-A-induced tumorigenesis.  
We found that there is a correlation between 
sensitivities to both UV and Aurora-A inhibitor 
VX-680 and the phosphorylation status of Akt Ser473. 
Three of Aurora-A stable clones isolated independ-
ently demonstrated similar response to these stimuli. 
Although we recognize that other cell types need to be 
studied, we consider that collaboration of Aurora-A 
and Akt pathway is crucial for cell transformation. It 
has been demonstrated that Aurora-A inhibitor, 
VX-680, can cause cell death of series of human cancer 
cell lines (12). In our cell culture model, cells showed 
apoptotic outcome in response to VX-680 treatment 
only in early time period of Aurora-A expression. It 
remains unclear why these cells not only stop the cell 
growth but also proceed to apoptosis after VX-680 
treatment. It is suggested that overexpression of 
Aurora-A can cause activation of pro-apoptotic 
pathway in early stages of cell culture, and that this 
apoptotic pathway is suppressed after long duration 
of Aurora-A overexpression. Inhibition of mTOR with 
rapamycin resulted in apoptosis, suggesting that 
mTOR is anti-apoptotic in Aurora-A cells. In that 
sense, inhibition of Aurora-A kinase by compounds in 
late stage of Aurora-A cancer may not suppress tumor 
phenotype effectively. In our previous 
MMTV-Aurora-A mice model, latency of tumor de-
velopment is quite long, so it is possible that 
Aurora-A triggers either activation of unidentified 
oncogenic pathways or inactivation of tumor sup-
pressive pathways happened in those time period. 
Identification of these ‘factors’ is quite important for 
detection and treatment of Aurora-A tumors. Int. J. Biol. Sci. 2009, 5 
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